BlossomHill Therapeutics, Inc.
Clinical-stage developer of small-molecule oncology therapeutics targeting EGFR, CLK, and KRAS — the Turning Point Therapeutics founding team’s second venture, listed on Nasdaq in August 2026 (Ticker: BLSM)
BlossomHill Therapeutics, Inc. (“BlossomHill” or “the company”) is a clinical-stage oncology therapeutics developer incorporated in June 2020 and headquartered in San Diego, California, with a small-molecule pipeline spanning oncology and autoimmune indications. In our assessment, the primary investment thesis rests less on the pipeline itself than on management’s repeatable track record: founder and CEO Dr. J. Jean Cui and co-founder and Executive Chairman Dr. Y. Peter Li both previously co-founded Turning Point Therapeutics, Inc. (Nasdaq: TPTX), took it public in 2019, and saw it acquired by Bristol Myers Squibb in 2022 for approximately $4.1 billion. In our view, this indicates the founding team has already demonstrated a complete value-creation cycle — discovery through clinical development, IPO, and large-pharma exit — once before, which we regard as a meaningful positive signal from a repeatability standpoint.
Ph.D., The Ohio State University; M.S./B.S., University of Science and Technology of China. Lead inventor of three FDA-approved oncology therapies — crizotinib (Xalkori), lorlatinib (Lorbrena), and repotrectinib (Augtyro) — which we regard as the single most important qualitative proof point for assessing the pipeline’s probability of clinical success. Following a decade at Pfizer/SUGEN (1999–2013, Senior Principal Scientist and Associate Research Fellow), she co-founded Turning Point Therapeutics in 2013 and served as CSO and director (2013–2020), where she designed the macrocyclic platform used to overcome resistance mutations. Recipient of the 2011 National Inventor of the Year award, a two-time ACS Heroes of Chemistry honoree (2013, 2021), and an elected member of the National Academy of Engineering.
MBA, UC Berkeley Haas School of Business. Co-founded Turning Point Therapeutics with Dr. Cui in 2013, serving as Chairman and CEO through 2018 and raising a cumulative $147 million across four venture rounds, before continuing as a director through the company’s $191 million IPO in 2019. In our assessment, Dr. Li’s capital-markets access and financing execution are a key variable underpinning the company’s fundraising track record.
A practicing oncologist and co-author of the first published description of the EGFR C797S resistance mutation — the very mechanism BH-30643 is designed to overcome. We view this as a positive indicator that the company holds internal clinical authority over the unmet-need indication it is targeting.
A substantial portion of the C-suite — Jason Keyes (EVP & CFO), Vincent Liptak (General Counsel), Zachary Zimmerman (SVP, Clinical Development), Armin Graber (SVP, Translational Medicine, CDx & Biomarkers), and Eugene Y. Rui (SVP, Chemistry) — previously worked together at Turning Point. We view this as a “team reunion” structure that materially lowers the organizational risk typically associated with early-stage team-building.
The board also includes healthcare-focused institutional investors who joined via the Series A and B rounds — Bihua Chen (Cormorant Asset Management), Carl L. Gordon (OrbiMed Advisors), and George J. Lee (Hercules BioVentures Partners) — which in our view constitutes a governance structure with substantial capital-markets experience.
The company positions itself as a “drug design company” that engineers small molecules against three targets with clearly defined unmet need in oncology — EGFR, CLK (CDC-like kinase), and KRAS. The pipeline comprises two clinical-stage assets and one preclinical asset, with initial clinical data presented at the 2026 ASCO and EHA annual meetings, respectively.
A non-covalent, macrocyclic “OMNI-EGFR” inhibitor being evaluated in patients with EGFR-mutant non-small cell lung cancer (NSCLC) in the global Phase I/II SOLARA trial. The program specifically targets patients who develop C797S-mediated resistance following third-generation EGFR TKI therapy — a population for which no approved oral targeted therapy currently exists. The company plans to seek an end-of-Phase I meeting with the FDA in Q4 2026 regarding a potential accelerated approval pathway, with first-patient dosing in a registrational Phase II trial targeted for Q1 2027.
Phase I/II · SOLARAA macrocyclic CDC-like kinase (CLK) inhibitor targeting aberrant RNA splicing. A Phase I/Ib trial is underway in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS), evaluating both monotherapy and combination with venetoclax. Preliminary anti-leukemic activity — including in patients with prior venetoclax-based treatment — was presented at the 2026 EHA congress.
Phase I/IbA switch-II-targeting pan-KRAS inhibitor currently in IND-enabling preclinical studies, with an IND submission planned for Q1 2027; related next-generation KRAS programs were disclosed at the 2026 AACR meeting. We view this as a third growth option beyond EGFR and CLK, but given its preclinical stage, we believe its contribution to valuation should be weighted conservatively at this time.
Preclinical · IND targeted Q1 2027Platform methodology: the company states that it applies a consistent approach across its pipeline — identifying the structural liabilities of existing therapies through a deep understanding of disease and protein structure, then designing novel chemical scaffolds to address them. We note that this remains a qualitative, company self-description, and we are not aware of independent, third-party validation data for platform efficacy.
Since its 2020 founding, the company raised more than $257 million on a self-reported basis across four pre-IPO rounds — from an angel round through a Series B bridge — over roughly six years, before completing its Nasdaq IPO in August 2026. Healthcare-focused institutional investors, including Cormorant Asset Management, OrbiMed, and Vivo Capital, participated continuously from the Series A round through the final pre-IPO round. In our view, this cross-round continuity is a meaningful indicator of sustained insider conviction.
The company closed an angel round roughly seven months after its June 2020 incorporation. The amount is not disclosed in available databases; given that a Series A followed within approximately two months, we believe this round likely functioned as bridge-style capital.
Led by Cormorant Asset Management, with Hercules BioVentures Partners, OrbiMed Advisors, and Vivo Capital participating as co-leads. Bihua Chen (Cormorant), George J. Lee (Hercules), and Carl L. Gordon (OrbiMed) joined the board, establishing a healthcare-focused institutional governance structure from the outset.
Led by Colt Ventures, with existing investors Cormorant, OrbiMed, Vivo Capital, and Hercules BioVentures joined by new participants Plaisance Capital Management and H&D Asset Management. The round brought cumulative funding to $173 million and was used to advance the lead pipeline asset into clinical development and to expand the pipeline more broadly.
Notably, the round was led by Janus Henderson Investors, a public-market asset manager, contributing approximately $20 million — an unusual instance of public-market investor participation at the private stage, which we interpret as a deliberate strategy to secure a crossover investor ahead of the IPO. Cormorant (15.5% of pre-IPO shares) and OrbiMed (9.8% of pre-IPO shares) participated alongside Vivo Capital, BioTrack Capital, Brahma Capital, and Plaisance Capital Management.
Pricing progression: the company filed its initial S-1 on July 16, 2026 (targeting up to $100 million); on August 3, an amended registration statement (S-1/A) raised the offering to 7.3–8.0 million shares in a $15–$17 range, targeting approximately $125 million; on August 6, the deal was upsized to 9,375,000 shares and priced at $16.00 per share, for total gross proceeds of $150 million; shares began trading on the Nasdaq Global Select Market under the ticker “BLSM” on August 7.
Underwriting syndicate: J.P. Morgan, Leerink Partners, and Guggenheim Securities served as lead book-running managers, with LifeSci Capital and H.C. Wainwright & Co. as joint book-running managers. Underwriters were granted a 30-day option to purchase up to an additional 1,406,250 shares.
• Shares offered: 9,375,000 shares (all newly issued by the company)
• Offering price: $16.00 per share (near the top of the initial $15.00–$17.00 range)
• Gross proceeds: $150,000,000 (before underwriting discounts, commissions, and expenses)
• Over-allotment option: up to 1,406,250 additional shares (30 days)
• Listing venue: Nasdaq Global Select Market (Ticker: BLSM)
• Trading / closing dates: trading began August 7, 2026; closing expected August 10, 2026
① Cumulative pre-IPO capital raised: the company’s S-1 filings and press releases disclose “over $257 million,” while at least one third-party startup database (Tracxn) reports approximately $260 million — a discrepancy of roughly $3 million. We believe this likely reflects differing round-closing-date conventions or the inclusion/exclusion of options and warrants. This report defaults to the company’s self-reported figure as the primary source.
② Series B bridge closing date: sources vary between November 25, 2025 (Tracxn) and December 10, 2025 (CB Insights). As the company’s S-1 filing and press coverage specify only “December 2025,” this report uses that broader time frame rather than a precise date.
In our view, the company’s competitive advantage rests less on the pipeline itself than on the combination of three factors: a proven serial-founder team, target selection against clearly defined unmet need, and continuity of institutional investor support. This combination does not eliminate the clinical-data risk inherent to any early-stage biotech, but we believe it materially lowers execution risk relative to peers.
Co-founders Dr. Cui and Dr. Li previously took Turning Point Therapeutics public ($191 million IPO, 2019) and through to acquisition by Bristol Myers Squibb ($4.1 billion, 2022). We view this as evidence of a repeatable process rather than a one-time success — an asset we regard as among the scarcest in early-stage biotech investing.
The same team that established the macrocyclic compound design methodology at Turning Point is reapplying it at BlossomHill. All three pipeline programs — EGFR, CLK, and KRAS — share the same “identify the structural liability, design a novel scaffold” methodology, which we view as an approach that provides a degree of platform-level risk diversification.
The C797S-mediated EGFR resistance population targeted by lead asset BH-30643 currently has no approved oral targeted therapy. CMO Dr. Oxnard’s role as the first to publish a description of this resistance mechanism lends scientific coherence to the clinical strategy, though the pace of competing programs from Dizal and ArriVent remains a risk factor requiring ongoing monitoring.
Cormorant Asset Management and OrbiMed participated in every round from the 2021 Series A through the 2025 Series B bridge, while Janus Henderson Investors, a public-market asset manager, joined as lead investor in the final pre-IPO round. We interpret this cross-round investor continuity and the arrival of a crossover investor as a positive signal for post-IPO share-price stability.
Organizational risk assessment: the fact that a substantial portion of the C-suite — CFO Jason Keyes, General Counsel Vincent Liptak, SVP Clinical Development Zachary Zimmerman, SVP Translational Medicine Armin Graber, and SVP Chemistry Eugene Rui — previously worked together at Turning Point substantially mitigates the early-stage team-building risk typical of new clinical biotechs. At the same time, we note this also concentrates institutional knowledge within a small, closely linked group, which constitutes a degree of key-man risk. We flag this as a two-sided consideration.